ANTICALINS: INHALABLE BIOLOGICALS FOR SEVERE ASTHMA

Abstract

This grant aims to develop a new class of medicines called 'anticalins'. Anticalins behave like a successful class of medicines called monoclonal antibodies (mAbs). MAbs are too fragile and large to be inhaled to treat lung disease but anticalins are small and robust. We will be developing an anticalin (PRS-060) which blocks damaging immune reactions in severe asthma. By inhaling PRS-060 we hope to make a new and clinically useful medicine for a common form of poorly-controlled severe asthma.

Related publications (2)

Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation

John Nixon, Paul Newbold, Tomas Mustelin, Gary P Anderson, Roland Kolbeck

2017-01-01

The Art of Breathing

Gary P Anderson, Tom Kotsimbos

2016-12-01